Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...188189190191192193194195196197198...208209»
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Trial completion:  A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics (clinicaltrials.gov) -  May 7, 2019   
    P1,  N=15, Completed, 
    The combination of apatinib with oral etoposide shows promising efficacy and manageable toxicities in patients with platinum-resistant or platinum-refractory ovarian cancer, and further study in phase 3 trials is warranted. Recruiting --> Completed
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial initiation date, PARP Biomarker, Metastases:  Treatment of Carrying TP53 Harmful Mutations (clinicaltrials.gov) -  Apr 25, 2019   
    P1,  N=60, Not yet recruiting, 
    Further prospective randomized controlled clinical trials are urgently needed. Initiation date: Sep 2018 --> Jul 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) -  Apr 17, 2019   
    P4,  N=32, Completed, 
    Taken together, our findings indicate that SHR6390 is a novel CDK4/6 inhibitor with favorable pharmaceutical properties for use as an anticancer agent. Recruiting --> Completed | N=100 --> 32 | Trial completion date: Feb 2019 --> Oct 2018 | Trial primary completion date: Feb 2019 --> Oct 2018
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Journal:  Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. (Pubmed Central) -  Apr 17, 2019   
    Together, these results indicate that apatinib displays a marked cytotoxic activity against various types of NHL cells (including BL, MCL, and GCB- or ABC-DLBCL) both in vitro and in vivo. They also suggest that anti-NHL activity of apatinib might be associated with inhibition of tumor cell growth and induction of apoptosis as well as anti-angiogenesis by targeting VEGFR2 and its downstream Ras/Raf/MEK/ERK pathway.
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Journal:  PET response assessment in apatinib treated radioactive iodine-refractory thyroid cancer. (Pubmed Central) -  Apr 12, 2019   
    When a cut-off value of the target/background ratio at -20% was used, two PFS curves showed a significant difference (P = 0.0016). Hence, early assessment by 18FDG and 68Ga-NOTA-PRGD2 PET/CT was effective in the prediction and evaluation of RAIR-DTC treated with apatinib.
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Journal:  Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. (Pubmed Central) -  Apr 12, 2019   
    This survival benefit was mediated, at least in part, by the ability of plinabulin to inhibit tubulin polymerization and disrupt endosomal recycling. It was proposed a mechanism of compromised endosomal recycling of displaced KRAS through targeting microtubules that yields inhibition of protein kinase B, but not extracellular signal regulated kinase (ERK) signaling, therefore lending rationale to combination treatments of tubulin- and ERK-targeting agents in KRAS-driven cancer.
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Clinical, Journal:  Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report. (Pubmed Central) -  Apr 7, 2019   
    It was proposed a mechanism of compromised endosomal recycling of displaced KRAS through targeting microtubules that yields inhibition of protein kinase B, but not extracellular signal regulated kinase (ERK) signaling, therefore lending rationale to combination treatments of tubulin- and ERK-targeting agents in KRAS-driven cancer. Apatinib combined with chemotherapy and apatinib monotherapy as maintenance therapy could be a new therapeutic strategy for ESS.
  • ||||||||||  fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
    Biomarker, Journal, BRCA Biomarker, PARP Biomarker:  Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. (Pubmed Central) -  Apr 6, 2019   
    We further demonstrated that these two inhibitors function synergistically in eliminating TNBC and HGSOC cells; combining with HS10241 increased DNA double-strand breaks induced by HS10160 in cancer cells; and PARP1 tyrosine (Y)-907 phosphorylation (PARP1 p-Y907) can be an effective biomarker as an indicator of MET-mediated PARPi in HGSOC. Our results suggest that the combination of HS10241 and HS10160 may benefit patients bearing tumors overexpressing MET as well as those resistant to single-agent PARPi treatment.
  • ||||||||||  Clinical, Journal:  Drugs in Clinical Development for Fungal Infections. (Pubmed Central) -  Apr 5, 2019   
    We also discuss two glucan synthesis inhibitors: CD101, an echinocandin with an increased half-life, and SCY-078 with oral bioavailability and increased activity against echinocandin-resistant isolates...Two novel classes of antifungal drugs are also described: glycosylphosphatidylinositol inhibitors, and the leading drug APX001, which disrupt the integrity of the fungal wall; and the orotomides, inhibitors of pyrimidine synthesis with the leading drug F901318. Finally, a chitin synthesis inhibitor and progress on human monoclonal antifungal antibodies are discussed.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Enrollment open:  OPAL2: A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) -  Apr 5, 2019   
    P2,  N=144, Recruiting, 
    In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials. Not yet recruiting --> Recruiting